About the Journal

Download [This article belongs to Volume - 62, Issue - 08 (October 2022)]

Abstract : A metabolic disorder called hyperglycemia characterises diabetes mellitus. Insulin therapy is crucial for those with type 1 diabetes and severe type 2 diabetes. The most frequent delivery technique is still subcutaneous injection. Due to their advantages in reducing patient's discomfort, worry, and tension, non-invasive insulin delivery systems are being researched. The simplicity of administration and lack of hepatic first-pass metabolism make transdermal delivery techniques extremely popular. One of the most promising methods is microneedle technology, which uses painless, minimally invasive needles to inject insulin through the stratum corneum of the skin. This article will examine the development of MNs for transdermal delivery of insulin, including hollow MNs, dissolving MNs, which allow for precise control of insulin dosage.Insulin was localised using dissolving polymeric microneedle (MN) patches made of gelatin and sodium carboxymethyl cellulose (CMC). The ability of their in vitro skin implantation was tested by staining the skin after the patches were removed with tissue-marking dye. Optical coherence tomography (OCT) was utilised to track the MNs' current penetration depth, and scanning electron microscopy (SEM) was employed to analyse changes in the MNs over time. Thus demonstrates that using a gelatin/CMC MN patch for insulin delivery results in satisfactory relative bioavailability compared to a conventional hypodermic injection and can be a promising delivery method for medications containing poorly permeable proteins, such as those used to treat diabetes.